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1. Introduction 
1.1 Breast cancer and metastasis 
Despite progressive advances in the fields of screening, radiation and chemotherapy, 
metastasis remains the leading cause of more than 90% of breast cancer related deaths. In 
metastasis, a small, select group of cells develops the capacity to disseminate from the 
primary tumour, and circulate via the blood or lymphatic system to distant organs, 
developing tumours at these new sites. Metastasis is a highly inefficient process, where 
less than 0.01% of tumour cells are able to successfully seed at secondary organs (Chiang 
& Massagué, 2008). In order to emerge as metastatic, tumour cells must  progress through 
all of the steps of metastasis: invasion of tissues surrounding the primary tumour, 
intravasation into the circulatory system, survival in the circulation by evasion of the 
immune system or apoptosis, arrest in a distant capillary, extravasation, and finally 
proliferation in a distant organ (Fidler, 2003). These cells have often been referred to as 
decathlon athletes because of their aggressive biology. Once metastasis has occurred, 
conventional therapies are rendered less effective due to the nature of these cells. They are 
heterogeneous in their metastatic potentials, growing at different rates, with different 
invasive abilities and varying responses to drugs and treatment. It is also particularly 
difficult to detect the early stages of metastasis and assess the presence of minimal 
residual disease after treatment, owing to the microscopic routes of progression. Current 
methods used to predict the risk of metastasis and determine suitable treatment regimens 
are based on evaluation of tumour characteristics such as size, histological grade, lymph 
node involvement, and expression of treatment response markers like ER, PR and Her2 
receptors (Weigelt et al., 2005). These practices however, are invasive and limited in their 
prognostic value. They are able to identify only 30% of breast cancer patients with a high 
risk for metastasis (Weigelt et al., 2005). There is a significant need for the development of 
new early prognostic markers for metastasis. Ultimately, if the spread of cells from the 
primary tumour could be stopped, then deaths from metastasis could be prevented. 
Researchers continue to try and shed more light on the molecular alterations in tumour 
cells which lead to metastasis. 
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1.2 Circulating tumour cells 
The first observation of circulating tumour cells (CTCs) was made in 1867 by an Australian 
physician, Thomas R. Ashworth. He showed that cells found in the circulation were 
identical to those found in the original cancer; and that they may be able to explain the 
origin of multiple metastatic tumours (Ashworth, 1867). Current research has established 
that primary tumours themselves have a gene expression signature that is predictive of 
metastasis, and that the shedding of neoplastic cells into the circulation begins early on (van 
de Vijver et al., 2002). Furthermore, these tumour cells are able to develop the capacity to 
metastasize independently from the primary tumour, with a unique set of genetic 
aberrations (Schardt et al., 2005; Schmidt-Kittler et al., 2003). Targeting only the primary and 
metastatic tumours is insufficient to tackle breast cancer in a systemic manner. It appears 
that the ‘vehicles’ that are responsible for cancer spread may provide the supplementary 
molecular targets urgently needed.  Metastasis has been known to develop in patients with 
small primary tumours, and even in 2-4% of rare cases of undetectable primary tumours 
(Weigelt et al., 2005; Hüsemann et al., 2008).  Early breast cancer mouse models, as well as 
human samples show evidence of the spread of circulating tumour cells at early stages, 
completely independent of tumour size (Hüsemann et al., 2008). The number of tumour cells 
that enter circulation in mouse models is highest immediately after initial transformation, 
and these cells will accumulate additional mutations over time to eventually be selected for 
malignant growth in new organs (Hüsemann et al., 2008). However, not all patients with 
detectable spread of tumour cells will go on to develop metastasis (36-50% of patients show 
no detectable metastatic disease up to 22 years later) (Graves & Czerniecki, 2011). Many 
confounding factors in the secondary organ microenvironment will affect the transformation 
of these cells from dormant to metastatic. None the less, these findings are indicative of 
metastasis being an early event. Circulating tumour cells (CTCs) might be the earliest 
detectable cells with metastatic abilities and are emerging as a promising biomarker for 
breast cancer progression.  CTCs may affect cancer prognosis years before the onset of overt 
metastasis, and therefore improve risk assessment and help identify patients in need of 
additional treatment. The cells themselves may provide new targets for therapy to prevent 
their spread to distant sites. 
2. Clinical relevance of CTCs 
CTCs are found in the peripheral blood and are separate from disseminated tumour cells or 
DTCs, which are found in the bone marrow. DTCs are an independent prognostic marker 
for poor prognosis in breast cancer. In a meta-analysis of prospective studies with at least 10 
years of follow up data on 4703 metastatic breast cancer patients, 30.6% of patients had 
DTCs which were associated with tumour stage, lymph node involvement, tumour grade, 
and hormone receptor negative status (Braun et al., 2005). The acquisition of DTCs from 
bone marrow, however, is an invasive procedure, requiring a high standard of quality 
control for repeated draws from the iliac crest of patients (Pantel et al., 2008). Several studies 
have shown an association between the occurrence of DTCs and CTCs in early and 
metastatic breast cancer (Graves & Czerniecki, 2011). Therefore, the collection of blood 
samples from patients for analysis of CTCs without surgical intervention, is a more 
attractive alternative for clinical purposes. 
CTCs have been extensively characterized as epithelial tumour cells, large in size, with a 
high nuclear to cytoplasmic ratio, irregular nuclear shape, non-proliferative and in some 
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cases, apoptotic (Pantel et al., 2008; Aktas et al., 2009; Fehm et al., 2010; Ignatiadis et al., 
2011; Wikman et al., 2008). These are not exclusive characteristics however, and a great 
degree of phenotypic heterogeneity exists within this population of cells. 
CTCs have been reported in 70-100% of patients with distant metastatic spread and 46-71% 
of patients with local nodal involvement (Cristofanilli et al., 2004). A multicenter prospective 
study of 177 patients compared quantities of CTCs in relation to outcome and showed that 
metastatic breast cancer patients with more than 5 CTCs per 7.5mL of blood had a shorter 
progression-free and overall survival (2.7 months vs. 7.0 months and 10.1 months vs. >18 
months) (Cristofanilli et al., 2005). In a follow up study with the same group of patients, it 
was reported that the number of CTCs was a better indicator of disease progression than 
traditional techniques such as imaging with PET, CT or MRI scans (Cristofanilli et al., 2007; 
Bidard et al., 2008; Nelson, 2010; Liu et al., 2009). Similar associations have been found in 
patients with colon and prostate cancer. Notably, decreased levels of CTCs are seen in 
response to chemotherapy suggesting a role for the measurement of CTCs in treatment 
monitoring. Chemo-resistant CTCs have been shown to be Her2 positive, although they 
originated from Her2 negative primary tumours (Flores et al., 2010; Fehm et al., 2010). A 
proportion of these patients had metastatic tumours which were also Her2 positive. Such 
discrepancies were also found with ER, PR and EGFR status suggesting a critical role for 
CTCs in stratifying patients for treatment (Fehm et al., 2009).  Furthermore, epithelial-
mesenchymal transition (EMT) and stem cell characteristics, such as expression of Twist, 
and ALDH1 are detectable in CTCs of metastatic breast cancer samples (Aktas et al., 2009).  
Such markers might be associated with a stem-cell like subpopulation persisting after 
treatment, capable of survival, self-renewal and aggressive propagation of new tumours. 
Further exemplifying this hypothesis, it has been shown that some CTCs have a multidrug 
resistance protein (MRP) expression profile which correlates with ALDH1 expression. CTCs 
from patients who expressed more than 2 MRPs, had shorter progression-free survival, and 
resistance to chemotherapy (Gradilone et al., 2011). Both DTCs and CTCs were included in 
tumour marker assessment for breast cancer by the American Society of Clinical Oncology 
in 2007 (Harris et al., 2007). The report was based on studies rated at Level of evidence I and 
II (prospective randomized controlled trials, prospective therapeutic trials, or meta-analyses 
testing the utility of a marker). While acknowledging the immense research interest and 
publications in the field, the clinical utility of CTCs  and DTCs is yet to be established and 
requires further large scale studies, especially in early breast cancer (Harris et al., 2007).  
Clinically, the mere presence of CTCs is indicative of a negative prognostic impact and 
highlights a role for these cells as biomarkers of disease progression and drug response. 
3. Methods for enrichment of CTCs from blood 
CTCs are a rare cell population (approximately 1 in 100 million nucleated blood cells of 
breast cancer patients). Metastatic breast cancer patients have been reported to have a range 
of 0 to a few thousand CTCs per 1-10 mL of blood (Flores et al., 2010; Talasaz et al., 2009) , 
compared to early stage breast cancers which from the limited publications to date as well 
as results from our own laboratory, report a range of 0 to less than 10 CTCs per 7-20 mL of 
blood (Ignatiadis et al., 2011; Lang et al., 2009; Shaw et al., 2011). A major obstacle is 
obtaining a sufficient number of CTCs, void of contaminating white blood cells, for 
downstream purposes such as genome, transcriptome or proteome analysis. Enrichment is 
usually a pre-requisite to any detection or isolation protocol described. After enrichment, 
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detection of cells is improved at least 10,000-fold, depending on the technique. Several 
methods for enrichment of CTCs have been described – immunomagnetic bead separation; 
density centrifugation separation, size based exclusion, and flow cytometric separation. 
Each of these methods allows for either positive selection by targeting CTCs with epithelial 
markers (cytokeratin, EpCAM), or negative selection by targeting white blood cells with 
leukocyte markers (CD45). There is however, a common and significant caveat in these 
procedures; CTCs are enriched from blood using normal epithelial cell markers due to lack 
of CTC specific malignant cell markers. Also, there is the possibility that in the process of 
tumourigenic progression, some CTCs may in fact lose their epithelial markers during 
epithelial-mesenchymal transition, and thus would not be selected for. To address these 
shortcomings, different methods of enrichment are combined (double selection) in order to 
compliment each other, and a panel of markers is used to best ascertain the identity of cells 
being enriched for. 
3.1 Immunomagnetic bead enrichment 
In February 2008, the FDA approved the CellSearch® System (developed by Veridex, LLC 
- Johnson & Johnson, NJ) as the first, validated method to accurately detect and 
enumerate CTCs in order to monitor metastatic disease in cancer patients (Riethdorf et al., 
2007). This system incorporates the interaction of target cells with antibodies conjugated to 
magnetic nanoparticles or ‘immunomagnetic beads’. Once cells are bound to the magnetic 
beads, they are passed through a magnetic core, where they are selectively retained, while 
unbound cells flow through. They are then fixed and labeled with fluorescent tags for 
subsequent analysis and enumeration. The advantage of this system is that it allows the 
use of multiple markers for CTCs as well as non-CTCs to enable more reliable 
identification. The standard panel includes CTC labeling antibodies such as EpCAM, and 
cytokeratins, as well as leukocyte labeling antibodies such as CD45.  DAPI stains the 
nuclei to enable characterization of the multi-lobed nuclei, or low nuclear to cytoplasmic 
ratio seen in white blood cells compared to mostly high nuclear to cytoplasmic ratio seen 
in CTCs (Figure 1). 
Recently, the Her2 antibody was added to the panel of test markers (Ignatiadis et al., 2011). 
The entire system is automated, including computerized image analysis and acquisition 
(Figure 2). It appears to be the gold standard of CTC detection to date, with more studies 
being published, each validating its sensitivity which has been established as a median of 5 
CTC per 7.5mL of blood (Kraan et al., 2011; Ignatiadis et al., 2011; Savitri Krishnamurthy et 
al., 2010; Sandri et al., 2010; Van der Auwera et al., 2010; Bidard et al., 2010). 
Recently, a modified version of this system was released, known as the CellSearch® Profile 
kit. This system incorporates a fewer number of steps, providing only enrichment of cells 
with the immunomagnetic beads, followed by elution. This allows for isolation and further 
processing of viable cells for other purposes such as cytometric or molecular analyses such 
as IHC, TUNEL assays, FISH, RT-PCR or DNA assays (Flores et al., 2010). Fewer processing 
steps has also resulted in a greater than 20-fold increase in the yield of CTCs with a range of 
4 - 2432 CTCs per 7.5mL of blood (Flores et al., 2010).  In addition, a group of researchers at 
Stanford University, CA have developed their own system based on the immunomagnetic 
principle, called the Magsweeper (Talasaz et al., 2009). This device incorporates magnetic 
rods with plastic sheets, which undergo repeated capture-wash-release cycles to enhance 
specific binding of target cells while non-specifically bound cells are gently washed off. 
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Another innovative device that has branched out from this technology is the CTC-chip, 
recently developed by a group of researchers at Harvard University, MA(Figure 3). The 
CTC-chip uses micro-fluidic principles for the capture of viable CTCs from small volumes of 
blood. Immunomagnetic nanoparticles are replaced by 78,000 microposts over a surface of 
970 mm2, each coated with antibodies for EpCAM (Nagrath et al., 2007). Capture of CTCs 
from blood by the microposts is dependent on strict laminar flow and volume conditions, 
with optimal capture occurring at a flow rate of less than 2.5ml per hour (Nagrath et al., 
2007). Once bound to the posts, CTCs may be processed in a similar fashion as the 
CellSearch® system by fixation and fluorescent labeling for analysis. It appears to be an 
efficient system,  enriching CTCs  in the range of 5 - 1281 cells per 1mL of blood (Nagrath et 






Fig. 1. Schematic of immunofluorescent staining of a CTC (cytokeratin: red, CD45: green, 
DAPI: blue). Tumour cells (CTC) are identified by high nuclear to cytoplasmic ratio and 
cytokeratin expression in the cytoplasm. White blood cells (WBC) are identified by smaller 
cellular size and CD45 expression. 
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Fig. 2. Schematic of typical results obtained from the CellSearch® analysis of CTCs isolated 
from metastatic breast cancer patients. Composite analysis of 2 CTCs is displayed; with 
positive labeling for cytokeratin (CK), DAPI and Her2 (two intensities shown, >2.5 is 
diagnosed as Her2 positive)  and negative labeling for CD45 (leukocyte marker). 
 
 
Fig. 3. CTC-chip with microposts; blood flows over and through microposts at designated 
flow rate and volume for capture of CTCs. Enlarged schematic shows micropost coated with 
EpCAM antibodies (yellow) interacting with a complementary epitope on the CTC. 
The next generation of the CTC-chip is the Herringbone chip, with enhanced capture (26% 
improvement from the CTC-chip) and higher flow rates (4.8mL of blood per hour) (Figure 
4). The improved performance is the result of a platform consisting of angular flow paths or 
microvortices which allow for passive mixing of blood as it flows through the chip, 
significantly increasing the number of interactions between CTCs and the antibody coated 
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chip surface (Stott et al., 2010). In addition, the platform of the chip is made up of a 
transparent material, allowing for improved imaging options, both for transmitted light IHC 
staining as well as fluorescent staining (Stott et al., 2010).  
 
 
Fig. 4. Magnified representation of the asymmetric, grooved surface of the Herringbone 
CTC chip. Microvortices allow for enhanced number of interactions between CTCs and the 
EpCAM antibody coated surface of the chip.  
Despite the promise of performance of microfluidic devices, there remain two significant 
disadvantages to these systems. Firstly, since cells are not fixed, samples must be processed 
within 2 hours of collection to maintain cell viability and capture by the chip. This 
complicates multicenter studies or the clinical utility of this system worldwide until this 
device is made commercially available. Secondly, once captured, CTCs are bound to the 
chip, and any subsequent analysis must be performed on the chip itself. Although this is 
beneficial for visualization and enumeration type assays, it is not transferrable to nucleic 
acid based assays such as RT-PCR or DNA analysis. 
3.2 Physical properties based enrichment 
CTCs are also enriched based on their physical properties such as density and size. 
Protocols have been developed for density based separation where tetrameric antibodies aid 
in the formation of aggregates of white blood cells and red blood cells, called 
‘immunorosettes’ (Gertler et al. 2003). These aggregates are complex structures with a 
higher density than single CTCs. Centrifugation allows for a fast and convenient pelleting of 
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the blood cells, enriching CTCs in the interphase of blood serum and a separating medium 
such as Percoll™ or Ficoll™ (Gertler et al., 2003). Size based separation protocols utilize the 
property of tumour cells being at least twice the size of the majority of leukocytes (>20µm 
versus 8 - 10µm). Blood is passed through filters which, with the help of a gentle vacuum 
pressure, exclude CTCs and a small number of larger white blood cells such as macrophages 
and monocytes (Pinzani et al., 2006).  
One obvious advantage of this type of separation is that CTCs are not being selected for by 
epithelial cell surface markers which might be lost during the aforementioned EMT 
processes. While both of these methods of separation provide the advantage of enriching for 
viable CTCs, which may be collected and stained for cytopathological analysis or subjected 
to RNA or DNA analyses, the technology is quite elementary and imprecise, and fails to 
give reproducible data. Also, not all CTCs are greater than 8µm, and there will remain a 
proportion that will be missed by this technique as well. 
3.3 Evaluation of two prevalent methods of CTC enrichment 
In our laboratory, we have evaluated immunomagnetic and density centrifugation based 
methods of CTC enrichment using spiking experiments.  Quantities of 100, 1000, 104 and 105 
cells from the MCF7 breast cancer cell line were spiked into 10 mL of peripheral blood from 
healthy volunteers. RossetteSep™ (density centrifugation separation) and EasySep™ 
(immunomagnetic bead separation) kits from StemCell Technologies Inc. were used for 
negative selection of spiked MCF7 cells from blood. The RossetteSep™ kit resulted in a 
purer cell eluate compared with the EasySep™ kit which contained interfering residual 
magnetic beads, and white blood cell clumps. The disadvantage however, was the lack of 
sensitivity and automation of both methods. The level for retrieving spiked cells was 
determined to be less than 60% of 104 and 105 spiked cells. Cells spiked below this threshold 
were not retrieved by either method. 
We have since validated a method of CTC enrichment from blood using the autoMACS™ 
cell sorter (Miltenyi Biotec). This machine incorporates negative selection of CTCs and 
immunomagnetic, automated separation. Immunolabeled cells pass through a magnet 
containing a column made up of a porous matrix dense enough to allow single cell flow 
through (Gijs, 2004). Each single cell is analyzed and sorted as labeled (CD45 positive 
leukocyte) or unlabelled (CD45 negative CTC), and eluted through its respective port. This 
method parallels the principle of the FDA approved CellSearch® System. Spiking 
experiments showed a 1000-fold increase in sensitivity of cells recovered compared to 
previously tested techniques in our laboratory. Sensitivity of the assay was dependent on 
the volume of blood processed, which corresponded to the number of white blood cells 
present in the sample.  Addition of a red blood cell lysis step served two purposes; (1) to 
reduce background of interfering red blood cells and enhance immunomagnetic bead-white 
blood cell interactions; and (2) to pellet the remaining cellular fraction and allow exclusion 
of non-specific free RNA/DNA. MCF7 breast cancer cells spiked into 3 ml of blood from 
healthy volunteers showed 70-90% recovery of 10-100 spiked cells, respectively (R=0.8959).  
4. Genetic profiling of CTCs 
Enriched CTCs are subjected to two types of analyses – immunocytometric or RT-PCR based 
assays. Both methods allow for multiplexing of markers to increase specificity. Markers 
include cytokeratins, Her2, MET, MUC1, ESR1, TWIST, ALDH1, EGFR, Ki-67 and many 
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more. RT-PCR assays are the most frequently reported method of CTC detection, and have 
the highest sensitivity (1 CTC in over 1-10 million nucleated blood cells) (Ring et al., 2005; 
Gerges et al., 2010). RT-PCR assays also have the advantage of high-throughput efficiency 
and allow for the analysis of larger panels of genes ranging from a few up to 16 genes as was 
recently published (Sieuwerts et al., 2008). This study showed that the proof of principle 
experiment was successful for analysis of a panel of 96 genes in one single tumour cell. This 
result however is affected by a high background of white blood cell RNA in patient samples, 
and thus was limited to an exploratory set of 16 genes capable of differentiating expression 
profiles of CTC positive breast cancer patients from CTC negative breast cancer patients 
(Sieuwerts et al., 2008). Another study aimed to determine the global expression pattern of 
CTCs, using the Affymetrix GeneChip™ platform, and once again concluded that a different 
panel of 16 genes was expressed specifically in CTCs from metastatic breast cancer patients 
(Smirnov et al., 2005). Noticeably, this study also looked at CTCs originating from different 
cancer tissues, and found that CTCs derived from different cancers had unique expression 
patterns as well (Smirnov et al., 2005).  
The disadvantages of these methods of profiling are false expression signatures created from 
non-specific primers or staining, lack of expression of the marker of interest on CTCs in the 
sample, pseudogenes, and low expression of the marker of interest on non-malignant cells. 
Work done in our own laboratory demonstrated the use of RT-PCR techniques to enumerate 
CTCs in blood by correcting for a percentage of these types of false signatures (Iakovlev et al., 
2007). Blood from healthy human volunteers was spiked with 1-10,000 tumour cells from 
breast cancer cell lines. Also, free RNA from these same cell lines was spiked separately to 
determine false positive results from free RNA, and genomic DNA released from dying cells in 
blood. We were able to show that there is a linear relationship between the number of CTCs in 
blood, and the amount of CK19 RNA, with a reliable detection limit of 5 cells per mL of blood 
with Ct values <40 to correct for false positives. We also determined that by including a 
centrifugation step to pellet CTCs and separate them from other fractions of blood, most of the 
contaminating free RNA and DNA can be excluded. These techniques may prove useful for 
high throughput comparative quantification or analyses of CTCs in individual patients during 
treatment and subsequent follow up for clinical management purposes.  
RNA is highly unstable and is readily degraded once it is released from the cell. 
Comparatively, DNA based assays are much more reliable, robust and less technically 
demanding. Genomic characterization of CTCs has however been unachievable thus far. 
Even the most sensitive technique of CTC enrichment from blood does not provide a pure 
sample void of white blood cell contamination.  Furthermore, even if isolation of a pure CTC 
sample was achieved, genomic analysis would be quite challenging owing to the low 
numbers of cells in circulation. If the whole genome of CTCs can be profiled, we could 
identify novel genomic alterations specific to CTCs which may be utilized in the 
development of specific markers for CTCs in blood. Also, regions of altered DNA in CTCs 
from early breast cancer patients hold valuable prognostic genetic information for the 
progression of early breast cancer to metastasis.  
4.1 Isolation of single CTCs for DNA extraction 
Our laboratory has been involved in the testing and validation of various technologies to 
address the problem of specificity during isolation of CTCs in order to genomically 
characterize these cells. We have designed a protocol to isolate single CTCs using 
immunocytochemical staining and single cell laser capture microdissection (LCM), followed 
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by whole genome amplification (WGA) of DNA for high density copy number analysis 
(Figure 5).   
 








ICC staining to detect 
cytokeratin positive 
CTCs





Human SNP 6.0 
array
 
Fig. 5. Flowchart of steps involved in the isolation of single CTCs from the blood of patients 
with locally advanced breast cancer, for purposes of whole genome amplification (WGA) 
and high resolution copy number analysis. 
We used the autoMACS™ separator for immunomagnetic based enrichment for CTCs from 
20mL of blood drawn from patients with locally advanced breast cancer. Each blood sample is 
processed in 3mL aliquots for optimal enrichment of CTCs from blood, as determined from 
spiking experiments described earlier. Each aliquot is lysed for red blood cells, pelleted, and 
then resuspended in separation buffer containing magnetic beads conjugated to CD45 
antibodies. The aliquot is then processed, selecting for the CD45 negative fraction which 
consists of enriched CTCs. The enriched CTC suspension is transferred onto a glass slide using 
a Cytospin centrifuge. It is then fixed and stained with a pan-cytokeratin AE1/AE3 antibody. 
This mixture of cytokeratin antibodies recognizes the vast majority of both low and high 
molecular weight keratins; CK 1-19; except for CK17 and CK18. Once the primary and 
secondary antibodies are bound, the method of detection that we use is a third antibody 
conjugated to the enzyme glucose oxidase which is not expressed in mammalian cells (Hard et 
al., 1989). This property abolishes any non-specific staining that occurs with horseradish 
peroxidase or alkaline phosphatase methods of detection. These enzymes are expressed 
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endogenously in white blood cells and thus could react with the detection substrate resulting 
in false positives (Figure 6). Glucose oxidase, however, is absent from white blood cells, and 
will react with the detection substrate positively staining only those cells that were bound to 
the primary and secondary antibody. This crucial modification of the staining protocol allows 
for the certainty of true positives. Positively stained CTCs are then lifted off the slide using 






Fig. 6. Enriched cancer cells after spiking of MCF7 cells into blood from healthy human 
volunteers. (A) Ambiguous staining of CK positive tumour cells and residual white blood 
cells using horseradish peroxidase detection of antibodies. (B) Specific staining of CK 
positive tumour cells and negative background of white blood cells using glucose oxidase 
detection of antibodies. (C) and (D) Enriched single CTCs from locally advanced breast 
cancer patients using the validated protocol. 
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Fig. 7. Cytokeratin positive CTC isolated from the blood of patient with locally  
advanced breast cancer, before and after lifting off slide using single cell laser capture 
microdissection. 
4.2 Whole genome amplification of single cells 
While there are numerous studies in the literature that have successfully isolated and 
enumerated CTCs; there is no knowledge of the genomic alterations of CTC DNA. Our 
laboratory has been successful at amplifying the whole genome of single CTCs in order to 
obtain sufficient amounts of representative DNA for microarray analysis. Most commercial 
platforms require between 700ng – 1000ng of good quality genomic DNA. We have 
established a protocol for whole genomic amplification of single cells using a modified 
protocol of the WGA4 kit (Sigma). We obtained between 1.5 - 3µg of amplified genomic 
DNA from single cells, which is sufficient for the Affymetrix Genome-Wide Human SNP 6.0 
array. This platform currently provides the highest resolution of copy number and loss of 
heterozygosity data with coverage of greater than 2 million copy number and SNP probes 
across the entire genome.  Our protocol has been validated using MCF7 cell line DNA from 
as few as 2 single cells. Microarray data was analyzed using Genotyping Console software. 
Segmented data was analyzed separately for copy number losses and gains (SNP-FASST 
segmentation algorithm) to identify significant genomic alterations. To begin analysis, we 
first noted regions of genomic aberrations in the MCF7 cell line that were previously 
described, and then compared this existing data to regions we obtained with the Affymetrix 
SNP 6.0 array (Shadeo et al., 2006 & Przybytkowski et al., 2011). Analysis shows expected 
aberrations in the MCF7 cell line were conserved across samples with amplified single cell 
starting material when compared to unamplified DNA (p<0.000001, 75% concordance). We 
improved this protocol by introducing a ligation step after genomic amplification. The 
average size of fragments that probes on the Affymetrix microchip bind to are 700-1000bp 
long. After WGA however, most DNA fragments are less than 500bp. Ligating these small 
amplified DNA fragments produces larger fragments of DNA for processing on the 
microchip, which in turn allows for more SNP and copy number calls to be made. 
Concordance was improved to greater than 90% after optimization (p<0.000001) (Figures 8-
10 and Table 1).  
20x  20x  
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Fig. 8. Comparison of Log2 ratios of copy number between unamplified genomic DNA from 
MCF7 breast cancer cells (top) and amplified DNA from 2 single MCF7 cells (bottom). 
Noticeably, although single cells produce more noisy probe calls (blue dots), copy number 
gains (green) and losses (red), as well as segmentation (black horizontal lines) are 
significantly conserved across single cell amplification, with 92% concordance. Analysis was 
performed using Nexus Copy Number software with the following parameters: significance 
threshold p<1.0E-6; maximum contiguous probe spacing = 1Mbp;  minimum probes per 
segment = 10; Log2 ratios: gain >0.2; high gain > 0.6; loss < -0.2; high loss < -1.0. 
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Amplified DNA from 2 single cells 
 
 
Fig. 9. Moving average of probes (1000 Kb) shows reproducible data between unamplified 
DNA and amplified single cell DNA from MCF7 breast cancer cells. Analysis was 
performed using Nexus Copy Number software with the following parameters: significance 
threshold p<1.0E-6; maximum contiguous probe spacing = 1Mbp;  minimum probes per 
segment = 10; Log2 ratios: gain >0.2; high gain > 0.6; loss < -0.2; high loss < -1.0. 
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Fig. 10. Copy number heat maps of chromosomes 1, 13 and 16 illustrating genomic gains 
(yellow) and losses (red) in the MCF7 breast cancer cell line; corresponding chromosomal view 
showing genomic gains (green) and losses (red), shown to the right. Each row represents one 
sample (Rows correspond with - 1: unamplified genomic DNA, 2-4: amplified DNA from 2, 3 
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Subsequently, CTCs isolated from patients with locally advanced breast cancer were 
processed using this protocol. This is an interesting subgroup of breast cancer patients, as 
they have locally invasive, larger primary tumours (>5cm) and the cancer has usually 
metastasized to the lymph nodes but not beyond. Thus they are a subgroup of early 
metastatic patients, however the cancer is advanced enough for there to be a high likelihood 
of the presence of detectable numbers of CTCs for genetic analyses. From a total of 31 
patients, CTCs were detected in 58% with a range of 1-20 cells per 20 mL of blood. We are 
currently performing microarray data analyses on these samples, with the goal of 
addressing some of the research questions discussed below. 
 






Amplified genomic 733884 700714 96 
Amplified genomic Amplified 2 cells 687896 633305 92 
Amplified genomic Amplified 3 cells 706094 660446 94 
Amplified genomic Amplified 5 cells 663709 567244 86 
Amplified 2 cells Amplified 3 cells 680912 629454 93 
Amplified 3 cells Amplified 5 cells 656417 568087 87 
Amplified 2 cells Amplified 5 cells 644176 558169 87 
Table 1. Concordance results of SNP calls made between samples of MCF7 breast cancer 
cells. SNP call concordance is accurately conserved between the unamplified genomic and 
amplified genomic samples at 96%. Single cell samples are compared to the amplified 
genomic sample for concordance so as to control for variability introduced by the WGA 
protocol. SNP call concordance is accurately conserved in amplified single cell samples 
(amplified genomic vs 2, 3, and 5 cells). A test for precision and reproducibility of the WGA 
protocol was also performed by comparing concordance of SNP calls within amplified 
single cell samples (2vs3, 3vs5, and 2vs5). Analysis performed with Genotyping Console 
software. 
Breast cancer is a heterogeneous disease which can be classified into 5 accepted molecular 
subtypes. Luminal A tumours tend to be ER+/PR+/Her2-, respond well to hormone 
therapy and have the most favourable outcome; Luminal B tumours tend to be 
ER+/PR+/Her+; Her2+ tumours are ER-/PR-; Basal tumours which are ER-/PR-/Her- tend 
to be the most aggressive, demonstrate the worst prognosis and have limited therapeutic 
options; and lastly the normal-like tumours are not clearly defined, and display a putative-
initiating stem cell phenotype (Perou et al., 1999, 2000; Sørlie et al., 2001, 2006). Using the 
genomic profiles generated from CTCs, copy number signatures could be configured to 
determine the predictive power of CTC genomic profiles in the subtyping of breast cancer 
based on clinical parameters of the primary tumour. Additionally, genomic profiles of 
matched primary and CTC samples could be analyzed for common and unique regions, to 
identify alterations involved in disease progression. The utility of CTC genomic profiles 
could also be extended to the monitoring of patient response to chemotherapy and other 
treatments. Decrease in CTC numbers is an already established phenomenon in good 
response and prognosis of patients undergoing treatments. It would be interesting to 
investigate the idea that CTCs themselves have a genetic signature capable of stratifying 
patients into responders and non-responders to various treatment regimens. The 
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characterization of genomic signatures of CTCs could pave the way to the development of 
biomarkers of disease subtype, progression to metastasis and response to treatment. In the 
future, a simple blood based assay could detect high risk patients, guide treatment options, 
identify new drug targets, and thus illuminate the process of metastasis. 
5. Future directions: Challenges and applications 
Although there is substantial evidence showing the prognostic value that CTCs hold in 
metastatic breast cancer, their clinical significance, especially in early breast cancer remains 
unclear.  There are no reports or studies on the presence of CTCs in ductal carcinoma in situ 
(DCIS) (Graves & Czerniecki, 2011). Numerous ongoing trials and studies are attempting to 
shed more light on this field. The Southwest Oncology group aims to determine the clinical 
value of CTC analyses for monitoring therapies. They are addressing the question of how 
beneficial serial CTC counts are for non-responding patients to the first-line of 
chemotherapy to determine if they should be placed on an alternative treatment regimen. If 
elevated CTCs are indeed informative, then enumeration assays could potentially replace 
the existing option of waiting for clinically detectable evidence of progressive disease. The 
DISMAL project hopes to identify new prognostic or therapeutic targets via the molecular 
characterization of CTCs and primary tumours. They aim to determine if there is a 
correlation between the profiles of primary tumours and the occurrence of CTCs, and if so 
are these profiles informative for processes responsible for early tumour cell dissemination? 
The SUCCESS trial indicates that CTCs do in fact play a prognostic role in early breast 
cancer, where the presence of just one single CTC has the ability to predict poor disease-free 
survival, distant disease-free survival, as well as overall survival. Various other ongoing 
trials are asking questions such as what similarities CTCs have with matched primary 
cancers, and whether the Her2 status of CTCs can predict a patient’s response to 
trastuzumab, especially in those cases where the primary tumour has been removed and 
CTCs persist (Pantel et al., 2008)? 
The current state of technologies in this field does not allow for the differentiation between 
CTCs of prognostic value or metastatic potential from those that are merely in circulation for 
a few hours destined for apoptosis or destruction by the immune system.  Less than 0.01% 
of CTCs in circulation will lead to overt metastasis. CTCs that escape immune surveillance, 
or adjuvant treatments are believed to be a more aggressive subpopulation of 
chemoresistant, stem-cell like (CD44+/CD24-) tumour cells. There have been reports on the 
low concordance between markers such as Her2, ER/PR and EGFR expression in CTCs 
compared to primary tumours from the same patient. Furthermore, EMT and stem cell 
characteristics, such as expression of Twist, and ALDH1 are detectable in some CTCs of 
metastatic breast cancer patients. Expression of EMT markers is what allows cells to evade 
apoptosis, migrate to distant sites and develop resistance to therapies (Kasimir-Bauer 2009). 
The property of heterogeneity seen in primary tumours seems to apply to CTCs as well and 
has very important implications with respect to treatment alterations over the course of the 
disease.  The other side of this argument however is that if breast cancer is heterogeneous, 
how useful is information derived from a single CTC? Essentially, this question is not too 
different from one that is asked of small biopsy samples taken from one area of a 
heterogeneous primary tumour. How representative is a biopsy of the true systemic cancer? 
Discrepant HER2 amplification found between primary tumours, metastatic tumours, and 
CTCs raise further questions about the current protocols used in diagnosis and treatment 
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decisions. New technologies like deep sequencing might enable us to delve into the true 
heterogeneity between single cancer cells. It will also allow us to study cancer cell line 
models, and determine how similar single cells from cancer cell lines really are, are they 
different when grown as tumours in vivo and do they produce genetically different 
tumours? Molecular profiling studies will help researchers to investigate this issue further.  
Overall, we are not yet at a point where we can clearly list the biological or molecular 
characteristics that define a CTC. We first need to standardize methods of analyses of CTCs 
to advance its utility in the clinic. There is a substantial amount of research interest in this 
field, and newer, better technologies enter the market steadily. It is entirely possible that 
different technologies are currently detecting different subsets of the CTC population 
(Nelson, 2010). What role does time of sampling, amount of sample drawn or individual 
patient characteristics have on the quality of the assay, are a few of the questions that will 
need to be tackled. More studies need to be developed around CTCs present in early breast 
cancer, and their presence and usefulness should be correlated with clinicopathological 
data, and gene expression data derived from currently recommended breast cancer 
prognostic markers and tests, for eg: Mammaprint and Oncotype Dx (Krishnamurthy et al., 
2010). CTCs have the potential of being established as a reliable prognostic or diagnostic 
biomarker for early breast cancer, progression to metastasis, response to treatment, and 
development of anti-metastatic drugs. Given the current interest and impetus in CTC 
research and technology, this milestone could be reached in the near future. 
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